What is ArunA Bio?
Founded in 2003 and based in Athens, Georgia, ArunA Bio specializes in the development of neural stem cell therapies and drug toxicity assays. The company's core technology leverages the natural ability of neural exosomes to traverse the blood-brain barrier. By enhancing the body's inherent anti-inflammatory, self-repair, and protective mechanisms, ArunA Bio aims to address a range of challenging medical conditions. Its research is positioned at the intersection of regenerative medicine and neurobiology, seeking novel therapeutic pathways.
How much funding has ArunA Bio raised?
ArunA Bio has raised a total of $20.2M across 4 funding rounds:
Private Equity
$3.7M
Unspecified
$5.3M
Debt
$350K
Other Financing Round
$10.8M
Private Equity (2016): $3.7M, investors not publicly disclosed
Unspecified (2018): $5.3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Other Financing Round (2021): $10.8M, investors not publicly disclosed
Key Investors in ArunA Bio
PPP
Public-Private Partnership
What's next for ArunA Bio?
The recent major strategic investment signals a pivotal growth phase for ArunA Bio. With substantial capital backing, the company is poised to accelerate its research and development initiatives, potentially moving towards clinical trials and commercialization of its exosome-based therapies. This infusion of financing is expected to bolster its scientific endeavors, expand its operational capacity, and solidify its market position in the competitive biotechnology landscape. ArunA Bio's focus on exosome delivery mechanisms for the central nervous system represents a promising frontier in drug development.
See full ArunA Bio company page
